Physician profile
Daniela Iulia Prada
NPI 1174598551
$7,243.67
in general payments reported to CMS, 2019-2025
45 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $567 · 2021: $1,378 · 2022: $1,235 · 2023: $1,225 · 2024: $1,399 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,493.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,715.58 | 2019-2025 | |
| Lilly USA, LLC | $549.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $362.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $358.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $350.03 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $329.87 | 2022-2025 | |
| Astellas Pharma US INC | $323.01 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $305.47 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $255.98 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| E.R. Squibb & Sons, L.L.C. | $232.42 | 2020-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.64 | 2020-2025 | Ofev |
| Ironwood Pharmaceuticals, INC | $167.44 | 2019-2024 | Linzess |
| Xeris Pharmaceuticals, INC. | $157.61 | 2021-2024 | Gvoke Hypopen, Keveyis |
| Glaxosmithkline, LLC. | $153.52 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $149.51 | 2019-2023 | Airduo Digihaler |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Prada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.